SeQuent Scientific Limited (SeQuent), which has businesses across Animal Health (Alivira) & Analytical Services today announced its financial results for the fourth quarter and full year ended March 31, 2019.
- FY19 Revenues at Rs.10,393 mn up by 22%, EBITDA at Rs.1,327 mn, up by 53%
- FY19 PAT at Rs. 569 Mn, up 5.6x
- Q4FY19 Revenues at Rs. 2,819 mn up by 21%, EBITDA at Rs.402 mn up by 31%
- EPS at Rs. 2.0, Board recommends dividend of Rs. 0.2 per equity share (10%)
Commenting on the Company's performance, Manish Gupta, Managing Director stated -This has been a year of strong performance wherein our Revenue and EBITDA grew by 22% and 52% respectively, with a 250 bps margin improvement and a 5.6x growth in PAT. The all-round growth was fueled by execution excellence across both APIs and formulations.
We have significantly scaled up our capabilities during FY19 with the addition of an injectable manufacturing facility in EU, expanding our formulations R&D capabilities and commercialisation of two products in US from our API facility in Vizag.
With the twin levers of scale and operating efficiencies playing out, our return ratios have improved resulting in robust operational cashflow. This reflects in the upward revision of credit rating during the year to A-. With a differentiated strategy, favourable environment and all the building blocks in place, we are well on course to create sustainable value for our stakeholders."
Shares of SEQUENT SCIENTIFIC LTD. was last trading in BSE at Rs.69 as compared to the previous close of Rs. 70.6. The total number of shares traded during the day was 39227 in over 333 trades.
The stock hit an intraday high of Rs. 71.25 and intraday low of 68.7. The net turnover during the day was Rs. 2752577.